Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.
Twist Bioscience Corporation (NASDAQ: TWST) is a synthetic biology and biotechnology company whose news flow reflects its focus on synthetic DNA tools, silicon-based DNA synthesis and research-enabling technologies. Company announcements frequently describe Twist as a mid-cap growth and value biotech company serving customers in medicine, agriculture, industrial chemicals and defense, where its DNA-based products support research and development programs.
On this page, readers can follow TWST news related to product launches, collaborations, financial updates and corporate developments. Recent press releases have highlighted the launch of research-grade plasmid DNA preps for nucleic acid therapeutics research, including animal origin-free and transfection-grade options with specific quality attributes and target yields. Other announcements cover expanded collaborations, such as the Trinity Freestyle Fast Hybridization workflow developed with Element Biosciences for the AVITI sequencing platforms.
Investors and researchers can also track earnings-related news, including preliminary revenue updates, quarterly and full-year financial results, and associated conference calls and webcasts. Corporate governance and compensation updates, such as inducement equity grants under Nasdaq Listing Rule 5635(c)(4), appear in Twist’s news stream as well.
In addition, Twist publishes news on biosecurity and policy engagement, including participation in a Science paper examining biosecurity screening practices in AI-assisted protein design. Conference presentations at major healthcare and life science events are also regularly announced. For anyone following TWST stock or the evolution of synthetic DNA technologies, this news page provides a centralized view of Twist Bioscience’s public communications and key milestones.
Twist Bioscience (NASDAQ: TWST) and Element Biosciences launched the Trinity Freestyle Fast Hybridization workflow for Element’s AVITI and AVITI24 sequencing platforms on October 6, 2025. The end-to-end solution enables sample-to-sequencer runs in as little as five hours and uses a rapid 1-hour hybridization with on-flow cell enrichment to remove binding, wash, amplification and pooling steps. Under an expanded agreement, Twist gains exclusive access to the Trinity Freestyle workflow for use with Twist’s library prep kits, including Enzymatic Fragmentation Kit 2.0 and FlexPrep UHT. The integration aims to provide compatibility with P5/P7-adapted libraries and Twist unique dual indexes, with expanded support subject to further validation.
Twist Bioscience (NASDAQ: TWST) on October 2, 2025 announced co-authorship of a peer‑reviewed paper in Science titled “Strengthening nucleic acid biosecurity screening against generative protein design tools.”
The study, led by Microsoft with industry and scientific partners including the International Gene Synthesis Consortium, ran a red‑teaming exercise showing some AI‑designed protein variants could evade standard biosecurity screening. Twist and collaborators used the results to develop patches and new screening strategies to improve detection of engineered sequences. The paper emphasizes iterative improvement, cross‑industry collaboration, and foresight to mitigate AI‑related biosecurity risks while noting the tested sequences were digital and their pathogenicity if manufactured is unknown.
Twist Bioscience (NASDAQ: TWST), a mid-cap biotech company, has announced upcoming presentations at two major healthcare conferences. CEO and co-founder Emily M. Leproust, Ph.D. will present at the Baird 2025 Global Healthcare Conference on September 9, 2025, at 9:40 am ET in New York City.
Additionally, the company will participate in one-on-one meetings at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 10, 2025. Both presentations will be accessible via webcast through the company's investor relations website, with replays available for 30 days after the events.
Twist Bioscience (NASDAQ: TWST) has announced a collaboration with Synthetic Design Lab (SDL) to support the development of novel antibody-drug conjugates for cancer treatment. The partnership leverages Twist's high-throughput expertise and proprietary tools to advance SDL's SYNTHBODY platform.
The collaboration combines Twist's capabilities in novel binder discovery services and high-throughput screening with SDL's innovative approach to developing next-generation therapeutics. This partnership aims to enhance the development of advanced therapeutic solutions for various cancer types.
Twist Bioscience (NASDAQ: TWST) has launched its new Oncology DNA Comprehensive Genomic Profiling (CGP) Panel, a research-use-only solution for tumor genomic profiling. The customizable panel covers 562 genes across major tumor types and can detect various genomic alterations including base substitutions, insertions, deletions, copy number variations, and gene rearrangements.
The panel also measures tumor mutational burden (TMB) and microsatellite instability (MSI), offering a flexible workflow compatible with multiple sequencing platforms. Designed for regional clinical labs, academic medical centers, and biopharma partners, the solution aims to provide a cost-effective and efficient alternative to existing CGP products and smaller panels.
Twist Bioscience (NASDAQ: TWST) has appointed Trynka Shineman Blake to its board of directors and audit committee. Ms. Shineman Blake, former CEO of Vistaprint, brings nearly three decades of experience in corporate governance, customer experience, digital transformation, and global marketing.
During her tenure at Vistaprint, she played a crucial role in scaling the business from under $100 million to over $1 billion in revenue. Her appointment comes at a strategic time as Twist advances toward adjusted EBITDA breakeven while maintaining focus on innovative solutions.
Twist Bioscience (NASDAQ: TWST) has announced its financial results for the third quarter of fiscal 2025, ended June 30, 2025. CEO Emily M. Leproust highlighted the company's strong balance sheet and disciplined cost management approach that supports their business execution.
The company will host a conference call and webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss the quarterly results. Interested participants must pre-register through the company's website to receive dial-in details.
Twist Bioscience (NASDAQ: TWST) has launched a new humanized transgenic (HuTg) mouse model to enhance its antibody discovery services. The new model offers a fee-for-service approach, eliminating the need for traditional licensing negotiations with providers.
The HuTg platform can be integrated with Twist's existing DiversimAb mouse model and B cell screening platforms, enabling researchers to generate human antibody candidates more efficiently. The technology accelerates lead discovery and optimization, reducing the timeline from months to weeks for identifying fully human hits.
Twist Bioscience (NASDAQ: TWST) has announced the granting of inducement equity awards to 36 newly hired employees. The awards total 70,254 equity units, comprising 56,182 restricted stock units (RSUs) and up to 14,072 performance stock units (PSUs).
The RSUs feature two vesting schedules over 48 months: one with 25% vesting after the first year followed by quarterly vesting, and another with straight quarterly vesting. The PSUs can be earned at 50%-140% of target based on performance metrics, with vesting through fiscal year 2027. These awards were granted under Twist's Amended and Restated Inducement Equity Incentive Plan in compliance with Nasdaq Listing Rule 5635(c)(4).
Twist Bioscience (NASDAQ: TWST) has scheduled its fiscal 2025 third quarter financial results announcement for August 4, 2025, before market opening. The company will host a conference call and live audio webcast at 8:00 AM Eastern Time to discuss the results and provide business updates.
Interested participants can access the financial results through the Investor Relations section of Twist's website. Those wishing to join via telephone must pre-register through the company's IR website to receive dial-in details and a unique PIN. The webcast replay will be available for two weeks following the call.
FAQ
What is the current stock price of Twist Bioscience (TWST)?
What is the market cap of Twist Bioscience (TWST)?
